Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Hepatology (Liver, Pancreatic, Gall Bladder)
Search Medical Condition
Nonalcoholic Steatohepatitis (NASH) Clinical Trials
A listing of Nonalcoholic Steatohepatitis (NASH) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (43) clinical trials
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
The primary objective of this study is to evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) fibrosis. The secondary objective of this study is to assess the safety and tolerability of SEL in subjects with NASH ...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
To evaluate whether selonsertib (SEL, previously known as GS-4997) can cause fibrosis regression and reduce associated complications in subjects with cirrhosis due to NASH.
Nonalcoholic Fatty Liver / Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease. It is caused by excess fat in the liver that leads to inflammation and tissue injury. People with type 2 diabetes, obesity, high cholesterol, insulin resistance, and high blood pressure may have NASH. ACRC Trials is conducting a research ...
TARGET-NASH: A 5-year longitudinal observational study of patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
Data collection on patients with NAFLD/NASH to determine the natural course of the liver disease and to determine if certain lifestyle changes or diet changes that may be recommended by your doctor can affect NAFLD/NASH. Optional blood samples may be collected once a year to identify and understand the genetic ...
A Phase 3 Clinical Trial for Patients with Nonalcoholic Steatohepatitis (NASH)
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Study Evaluating the Safety and Efficacy of Obeticholic Acid (study medication) in Subjects with Nonalcoholic Steatohepatitis (NASH).
Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. ClinSearch is enrolling volunteers with a condition called liver fibrosis from NASH in a study testing the effectiveness and safety of an investigational medication. Qualified participants may receive: Study-related medication at no cost Study-related medical ...
Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. If you have liver fibrosis due to Nonalcoholic Steatohepatitis (NASH), Wake Research Associates is enrolling volunteers with in a study testing an investigational medication.
Now Enrolling for NASH research study
If you have a diagnosis of nonalcoholic steatohepatitis (NASH) or risk factors of Fatty Liver Disease, such as being overweight, having high blood pressure, sleep apnea or diabetes, you may qualify for a Fatty Liver Research Study. Qualified participants receive study-related exams, medication and care from a board-certified physician at ...
NASH (Nonalcoholic Steatohepatitis) with Fibrosis of the Liver
Have you been told you have liver fibrosis from NASH? Considering other options? ClinSearch is enrolling participants in a clinical research study of the safety, tolerability and effectiveness of an investigational medicine designed for people with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis
A research study is being conducted to evaluate the safety and efficacy of an investigational combination of medication for Nonalcoholic Steatohepatitis (NASH) and liver fibrosis.
